| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2025―Feb―14 |
Impact of SARS-CoV-2 infection on clinical characteristics, antibody levels, and immune responses in patients with malignant hematological tumors |
Yan Li, Jing Zhang, Xiang Wang, Yan Wang, Ruili Wang, Yongzhen Chen, et al. (+2) Changkai Chen, Yuyang Tian |
| 2 |
[GO] |
2024―Jun―14 |
Antiviral combination regimens as rescue therapy in immunocompromised hosts with persistent COVID-19 |
Roberta Maria Antonello, Davide Marangoni, Filippo Ducci, Anna Barbiero, Tommaso Manciulli, Lucia Graziani, et al. (+10) Nicoletta Di Lauria, Lorenzo Menicacci, Lorenzo Paci, Benedetta Sordi, Lorenzo Zammarchi, Alessandro Morettini, Sara Tomassetti, Gian Maria Rossolini, Alessandro Bartoloni, Michele Spinicci |
| 3 |
[GO] |
2024―May―09 |
Comparison of bamlanivimab with or without etesevimab and casirivimab-imdevimab in clinical outcomes in patients with COVID-19: a systematic review and meta-analysis |
Mingyang Yang, Junzhao Liu, Linna Luo, Kaili Dai |
| 4 |
[GO] |
2023―Dec―14 |
Neutralizing monoclonal antibodies for the prevention of severe COVID-19: a retrospective study during Omicron BA.1 variant surge |
Claudia Bartalucci, Alessandro Limongelli, Laura Ambra Nicolini, Marta Ponzano, Stefania Tigano, Sara Tita Farinella, et al. (+15) Giuliana Carrega, Gemma Malerba, Federica Magnè, Elisa Balletto, Daniele Roberto Giacobbe, Giovanni Riccio, Giovanni Cenderello, Lucia Taramasso, Bianca Bruzzone, Antonio Vena, Antonio Di Biagio, Malgorzata Mikulska, Andrea De Maria, Chiara Dentone, Matteo Bassetti |
| 5 |
[GO] |
2023―Dec―04 |
Effectiveness of remdesivir-based therapy for moderate COVID-19: comparison of Omicron and other variant phases |
Atsushi Suzuki, Kensuke Fukumitsu, Jun Fukihara, Takuma Katano, Hisashi Kako, Yuri Maeda, et al. (+4) Makoto Ishii, Akio Niimi, Kazuyoshi Imaizumi, Etsuro Yamaguchi |
| 6 |
[GO] |
2023―Aug―23 |
Effect of SARS-CoV-2 vaccination in a vulnerable COVID-19 cohort: a real-life experience in an Italian Hospital |
Chiara Russo, Luca Tagliafico, Laura Labate, Marta Ponzano, Michele Mirabella, Federica Portunato, et al. (+10) Carmen Bellezza, Sara Mora, Eleonora Arboscello, Fiammetta Monacelli, Alessio Nencioni, Alessio Signori, Bianca Bruzzone, Mauro Giacomini, Chiara Dentone, Matteo Bassetti |
| 7 |
[GO] |
2023―Aug―22 |
Safety of Sotrovimab use in children with COVID-19: an Italian experience |
Elisabetta Venturini, Lara Fusani, Andrea Lo Vecchio, Sara Maria Scarano, Silvia Garazzino, Giulia Pruccoli, et al. (+4) Daniele Donà, Laura Lancella, Guido Castelli Gattinara, Luisa Galli |
| 8 |
[GO] |
2023―Apr―27 |
Successful treatment of persistent SARS-CoV-2 infection with nirmatrelvir/ritonavir plus sotrovimab in four immunocompromised patients |
Massimiliano Lanzafame, Martina Gottardi, Lorenza Guella, Lucia Collini, Giorgio Costa, Anna Guella, Sandro Vento |
| 9 |
[GO] |
2022―Sep―14 |
Effect of remdesivir on mortality rate and clinical status of COVID-19 patients: a systematic review with meta-analysis |
Carmine Sellitto, Graziamaria Corbi, Nicola Bertini, Tiziana Ascione, Maria Costantino, Giuliana Scarpati, et al. (+4) Ornella Piazza, Amelia Filippelli, Valeria Conti, Pasquale Pagliano |
| 10 |
[GO] |
2022―Jul―15 |
Early 3-day course of remdesivir in vaccinated outpatients with SARS-CoV-2 infection. A success story |
Periklis Panagopoulos, Vasilis Petrakis, Grigorios Trypsianis, Dimitrios Papazoglou |
| 11 |
[GO] |
2022―Apr―26 |
Carbapenem-resistant Klebsiella pneumoniae outbreak in a COVID-19 intensive care unit; a case-control study |
Pınar Ergen, M. Esra Koçoğlu, Müge Nural, Mert Ahmet Kuşkucu, Özlem Aydin, Ferda Y. İnal, et al. (+9) Hande Öztürk, Ayşe C. Üçişik, Hülya Çaşkurlu, Büşra Güneysu, Büşra Yildirim, Kenan Midilli, Yasemin Çağ, Ferhat Arslan, Haluk Vahaboglu |
| 12 |
[GO] |
2021―Oct―16 |
Drugs and liver injury: a not to be overlooked binomial in COVID-19 |
M. Vitrone, F. Mele, E. Durante-Mangoni, R. Zampino |
| 13 |
[GO] |
2021―May―25 |
Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center’s experience |
Murat Ayhan, Hatice Odabas, Nedim Turan, Deniz Tataroglu Ozyukseler, Osman Kostek, Gulin Alkan, et al. (+2) Evrim Abamor, Mahmut Emre Yildirim |
| 14 |
[GO] |
2021―Mar―26 |
Outcomes of diagnosed COVID-19 cancer patients: concerning results of a systematic review |
C. Nahshon, Y. Segev, M. Schmidt, T. Bar-noy, L. Ostrovsky, O. Lavie |
| 15 |
[GO] |
2021―Jan―13 |
Therapeutic options for COVID-19: a quick review |
Muhammad Sani Ismaila, Faruku Bande, Aminu Ishaka, Aminatu Abubakar Sani, Karla Georges |
| 16 |
[GO] |
2020―Oct―13 |
Exploring metastatic breast cancer treatment changes during COVID-19 pandemic |
Palma Fedele, Antonella Ferro, Valeria Sanna, Nicla La Verde, Ida Paris, Rita Chiari |
| 17 |
[GO] |
2020―Jun―12 |
Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection |
Periklis Panagopoulos, Vasilis Petrakis, Maria Panopoulou, Grigorios Trypsianis, Theano Penlioglou, Ioannis Pnevmatikos, Dimitrios Papazoglou |
|
